Companies
MicroPort Scientific
MicroPort and Lepu are among China's top cardiovascular-device companies, leading the domestic drug-eluting stent and pacemaker rankings built on the VBP winners' list.
- Country
- China
- Ticker
- HKG:0853
Cardiovascular implants
NMPA registered
cn
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Founded | 1998 | microport.com |
| Production site | Shanghai, Suzhou, Jiaxing, Shenzhen in China; Irvine, Memphis, Boston in the US; France, Italy, Germany, UK, Dominica, India, Costa Rica | microport.com · hkexnews.hk · www1.hkexnews.hk |
| Capacity | Combined annual output of 2 million sets of coronary stents and balloon catheters as of 2021, with a planned megafactory capacity of tens of millions of units. | microport.com |
| Regulatory approval | From the beginning of 2024 to September 2024, the group and its associates obtained 31 Class III initial registration certificates from the NMPA, and 102 additional initial registration certificates in 25 overseas countries and territories. | www1.hkexnews.hk |
| Revenue | Revenue of US$57,044 million reported in 2025 annual report (note: source data notation for revenue figures appears to be in thousands or specific financial reporting units, check source 11) | hkexnews.hk |
Independent sources: hkexnews.hk · www1.hkexnews.hk
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biomedical engineering & implants | regenerative-personalized | Medium | → |
| Implantable biosensors for chronic disease | diagnostics-medtech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.